OTC Markets EXMKT - Delayed Quote ? USD (BRRGF) Follow Compare 2.5000 0.0000 (0.00%) At close: October 31 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients. PR Newswire ? 25 days ago BRRGF 0.00% BerGenBio Second Quarter Results 2024: Solid clinical and financial progress BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update. PR Newswire ? 2 months ago BRRGF 0.00% BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today a collaboration with Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, to advance the clinical development of BerGenBio's selective AXL inhibitor bemcentinib in first line (1L) Non-Small Cell Lung Cancer (NSCLC) patients with STK11 mutations (STK11m). BerGenBio's on-going BGBC PR Newswire ? 2 months ago BRRGF 0.00% BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and Safety Monitoring Board (DSMB) for BerGenBio's Phase 1b/2a BGBC016 study confirmed acceptable safety at the highest dose tested in the Phase 1b. As a result, the DSMB also recommended that under the study protocol, no additional patients will be required for Phase 1b. PR Newswire ? 3 months ago BRRGF 0.00% BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update. PR Newswire ? 5 months ago BRRGF 0.00% BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi? BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan Biovitrum AB (Sobi?) (STO:SOBI), a specialized international biopharmaceutical company. PR Newswire ? 5 months ago BRRGF 0.00% BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (STK11m). PR Newswire ? 7 months ago BRRGF 0.00% BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented "Investigating the effects of AXL inhibition during respiratory viral infections" during the 6th Forum on Respiratory Infections in Glasgow, Scotland. PR Newswire ? 8 months ago BRRGF 0.00% BerGenBio Reports Third Quarter 2023 Financial Results BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended September 30, 2023, and provided a business update. PR Newswire ? 11 months ago BRRGF 0.00% BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that a poster presentation detailing additional data from a Phase II trial of bemcentinib in combination with MSD's anti-PD-1 therapy, KEYTRUDA? (pembrolizumab) in second line Non-Small Cell Lung Cancer (NSCLC) patients was presented on November 4th at the 2023 Society of Immunotherapy of Cancer Annual Meeting. PR Newswire ? 11 months ago BRRGF 0.00% Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is OBX Total Return Index Return BRRGF OBX Total Return Index YTD +9,900.00% +12.33% 1-Year +41.24% +12.97% 3-Year +8.23% +26.97%
